Streptococcus pneumoniae remains a major cause of morbidity and mortality worldwide. Two components of pneumococci are thought to be responsible for much of the deleterious inflammatory hot response, the thiol-activated secreted toxin pneumolysin and the peptidoglycan component of the ell wall. Both of these molecules have been shown to cause inflammatory changes in vitro studies in epithelial and neuronal cells, as well as activate monocytes and macrophages of the inactive immune system. Preliminary work in our laboratory supports the hypothesis that pneumolysin activates the innate arm of the immune system through a transmembrane receptor, Toll-like receptor 4 (TLR4), in synergy with peptidoglycan (a TLR2 ligand) and/or whole pneumococci. In addition, we have some preliminary data to suggest that the activation of the innate immune response by pneumolysin may greatly augment acquired immunity to pneumococcus as well. The scientific goals of this project are divided in two phases. In the first phase, the PI will study the TLR- dependent signaling pathway of pneumolysin, alone and in combination with peptidoglycan or whole pneumococci. Studies will be done to test the hypothesis that pneumolysin binds directly to TLR4. This phase will also include an intense didactic component, to complement the work in the laboratory. In the second phase, the PI will study the role of this pathway in the modulation of disease and acquired immunity to pneumococci. This phase of the project will test the hypothesis that TLR4-mediated cellular activation by pneumolysin plays an important role in the pathophysiology of pneumococcal disease. Pneumococci carrying mutations in the pneumolysin gene, with diminished or abrogated TLR4-signaling capability, will be studied both in vitro (in macrophages) and in vivo (in murine models of colonization and disease). The possible role of TLR4-mediated response to pneumolysin in the development of acquired immunity will be studied in the final aim of the proposal. The establishment of a link between the innate and the acquired arm of the immune response to pneumococcus may provide a better understanding of the mechanisms by which immunity to pneumococcus is acquired.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Clinical Investigator Award (CIA) (K08)
Project #
5K08AI051526-02
Application #
6623305
Study Section
Microbiology and Infectious Diseases B Subcommittee (MID)
Program Officer
Klein, David L
Project Start
2002-04-15
Project End
2004-03-31
Budget Start
2003-04-01
Budget End
2004-03-31
Support Year
2
Fiscal Year
2003
Total Cost
$128,520
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Lu, Ying-Jie; Yadav, Puja; Clements, John D et al. (2010) Options for inactivation, adjuvant, and route of topical administration of a killed, unencapsulated pneumococcal whole-cell vaccine. Clin Vaccine Immunol 17:1005-12
Lu, Ying-Jie; Gross, Jane; Bogaert, Debby et al. (2008) Interleukin-17A mediates acquired immunity to pneumococcal colonization. PLoS Pathog 4:e1000159
Srivastava, Amit; Casey, Heather; Johnson, Nathaniel et al. (2007) Recombinant bactericidal/permeability-increasing protein rBPI21 protects against pneumococcal disease. Infect Immun 75:342-9
Malley, Richard; Srivastava, Amit; Lipsitch, Marc et al. (2006) Antibody-independent, interleukin-17A-mediated, cross-serotype immunity to pneumococci in mice immunized intranasally with the cell wall polysaccharide. Infect Immun 74:2187-95
Srivastava, Amit; Henneke, Philipp; Visintin, Alberto et al. (2005) The apoptotic response to pneumolysin is Toll-like receptor 4 dependent and protects against pneumococcal disease. Infect Immun 73:6479-87
Malley, Richard; Trzcinski, Krzysztof; Srivastava, Amit et al. (2005) CD4+ T cells mediate antibody-independent acquired immunity to pneumococcal colonization. Proc Natl Acad Sci U S A 102:4848-53
Trzcinski, Krzysztof; Thompson, Claudette; Malley, Richard et al. (2005) Antibodies to conserved pneumococcal antigens correlate with, but are not required for, protection against pneumococcal colonization induced by prior exposure in a mouse model. Infect Immun 73:7043-6
Lipsitch, Marc; Whitney, Cynthia G; Zell, Elizabeth et al. (2005) Are anticapsular antibodies the primary mechanism of protection against invasive pneumococcal disease? PLoS Med 2:e15
Malley, Richard; Morse, Sarah C; Leite, Luciana C C et al. (2004) Multiserotype protection of mice against pneumococcal colonization of the nasopharynx and middle ear by killed nonencapsulated cells given intranasally with a nontoxic adjuvant. Infect Immun 72:4290-2
Malley, Richard; Henneke, Philipp; Morse, Sarah C et al. (2003) Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc Natl Acad Sci U S A 100:1966-71